Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Kejie Zhang; Aakash Desai; Dongfeng Zeng; Tiejun Gong; Peihua Lu; Michael Wang

doi:10.18632/oncotarget.13314

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Oncotarget. 2017 Feb 7;8(6):10748-10759. doi: 10.18632/oncotarget.13314.

Authors

Kejie Zhang¹, Aakash Desai^{2

3}, Dongfeng Zeng⁴, Tiejun Gong⁵, Peihua Lu⁶, Michael Wang²

Affiliations

¹ Department of Hematology, Zhongshan Hospital, Xiamen University, Fujian Medical University Clinic Teaching Hospital, Xiamen, China.
² Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ University of Texas Health Science Center, Houston, Texas, USA.
⁴ Department of Hematology, Xinqiao hospital, Third Military Medical University, Chongqing, China.
⁵ Institute of Hematology and Oncology, Harbin first Hospital, Harbin, China.
⁶ Department of Hematology, Hebei Yanda Ludaopei Hospital, Beijing, China.

Abstract

Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.

Keywords: Ixazomib; daratumumab; elotuzumab; multiple myeloma.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Boron Compounds / adverse effects
Boron Compounds / therapeutic use
Congresses as Topic
Glycine / adverse effects
Glycine / analogs & derivatives
Glycine / therapeutic use
Humans
Hydrazines / adverse effects
Hydrazines / therapeutic use
Molecular Targeted Therapy
Multiple Myeloma / drug therapy*
Multiple Myeloma / enzymology
Multiple Myeloma / immunology
Multiple Myeloma / pathology
Proteasome Inhibitors / adverse effects
Proteasome Inhibitors / therapeutic use*
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Signal Transduction / drug effects
Thiadiazoles / adverse effects
Thiadiazoles / therapeutic use
Treatment Outcome
Triazoles / adverse effects
Triazoles / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Boron Compounds
Hydrazines
Proteasome Inhibitors
Protein Kinase Inhibitors
Thiadiazoles
Triazoles
elotuzumab
selinexor
daratumumab
ixazomib
filanesib
Glycine